Comparison of cabozantinib (CABO) versus sunitinib (SUN) following first-line (1L) nivolumab plus ipilimumab (NIVO plus IPI) for metastatic renal cell carcinoma (mRCC): A target trial emulation using real-world data from the International mRCC Database Consortium (IMDC)

被引：2
|
作者：
Lemelin, A. [1 ]
Takemura, K. [2 ]
Boyne, D. J. [3 ]
Warkentin, M. T. [3 ]
Brenner, D. R. [3 ]
Cheun, W. Y. [3 ,6 ]
Wells, J. C. [4 ]
Labaki, C.
McGregor, B. A. [6 ]
Basappa, N. S. [7 ]
Meza, L. A. [8 ]
Pal, S. K. [8 ]
Beuselinck, B. [9 ]
Mckay, R. R. [10 ]
Szabados, B. E. [11 ]
Powles, T. B. [12 ]
Yuasa, T. [13 ]
Ludwig, L. [14 ]
Choueiri, T. K. [5 ]
Heng, D. Y. C. [2 ]
机构：
[1] Tom Baker Canc Clin, Med Oncol, Calgary, AB, Canada
[2] Tom Baker Canc Clin, Oncol Dept, Calgary, AB, Canada
[3] Univ Calgary, Oncol Dept, Oncol, Calgary, AB, Canada
[4] BC Canc Agcy, Oncol, Vancouver, BC, Canada
[5] Dana Farber Canc Inst, Med Genet Unit, Boston, MA USA
[6] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA
[7] Cross Canc Inst, Med Oncol Dept, Edmonton, AB, Canada
[8] City Hope Comprehens Canc Ctr, Med Oncol, Duarte, CA USA
[9] Univ Hosp Leuven, Dept Gen Med Oncol, Campus Gasthuisberg, Leuven, Belgium
[10] Univ Calif San Diego, Oncol, Moores Canc Ctr, La Jolla, CA USA
[11] Barts & London Queen Marys Sch Med & Dent, Med Oncol Dept, Canc Res UK Barts Ctr, London, England
[12] Queen Mary Univ London, Barts Canc Inst, St Bartholomews Hosp, Expt Canc Med Ctr, London, England
[13] JFCR, Urol, Canc Inst Hosp, Koto Ku, Tokyo, Japan
[14] Ipsen Biopharmaceut Canada Inc, Med Sci Liaison, Mississauga, ON, Canada
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1132
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1902P
引用
收藏
页码：S1023 / S1024
页数：2
相关论文
共 50 条
  • [31] Updated outcomes of patients with metastatic non-clear cell renal cell carcinoma (mnccRCC) treated with first-line (1L) therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
    Takemura, Kosuke
    Graham, Jeffrey
    Maj, David
    Zarba, Martin
    Wells, Connor
    Chehade, Razane El Hajj
    Eid, Marc
    Saad, Eddy
    Saliby, Renee Maria
    Lee, Jae Lyun
    Donskov, Frede
    Beuselinck, Benoit
    Jude, Evon
    McKay, Rana R.
    Basappa, Naveen S.
    Pal, Sumanta Kumar
    Porta, Camillo
    Agarwal, Neeraj
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [32] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648.
    Chau, Ian
    Ajani, Jaffer A.
    Doki, Yuichiro
    Xu, Jianming
    Wyrwicz, Lucjan
    Motoyama, Satoru
    Ogata, Takashi
    Kawakami, Hisato
    Hsu, Chih-Hung
    Adenis, Antoine
    El Hajbi, Farid
    Di Bartolomeo, Maria
    Braghiroli, Maria Ignez Freitas Melro
    Holtved, Eva
    Murphy, Mariela A. Blum
    Abdullaev, Sandzhar
    Soleymani, Samira
    Lei, Ming
    Kato, Ken
    Kitagawa, Yuko
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] Tivozanib (T) as first-line (1L) treatment of metastatic renal cell carcinoma (mRCC): A real-world outcome review in North-West of England (NWE), UK.
    Heseltine, Jonathan
    Allison, Jennifer
    Wong, Sam
    Prasad, Kellati
    Wong, Helen
    Oong, Zhu
    Charnley, Natalie
    Law, Andrea
    Parikh, Omi
    Pillai, Manon Rhys
    Waddell, Tom
    Griffiths, Richard
    Chow, Shien
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [34] Real-world outcomes of first-line dual immunotherapy versus combination VEGF immunotherapy in intermediate-poor risk metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Data Consortium (IMDC).
    Zarba, Martin
    Maj, David
    Wells, Connor
    Chehade, Razane El Hajj
    Ozay, Zeynep Irem
    Pal, Sumanta Kumar
    Beuselinck, Benoit
    Liow, Elizabeth Chien Hern
    Alva, Ajjai Shivaram
    Powles, Thomas
    Bjarnason, Georg A.
    Wood, Lori
    Kanesvaran, Ravindran
    de Velasco, Guillermo
    Lee, Jae Lyun
    Templeton, Arnoud J.
    McKay, Rana R.
    Suarez, Cristina
    Choueiri, Toni K.
    Heng, Daniel Yick Chin
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL)
  • [35] Molecular analysis of the HCRN GU16-260-Cohort A phase II study of first-line (1L) nivolumab (nivo) and salvage nivo plus ipilimumab (ipi) in patients (pts) with advanced clear cell renal cell carcinoma (accRCC)
    Zaemes, Jacob Peter
    Hugaboom, Miya
    Shah, Valisha
    Haas, Naomi B.
    McDermott, David F.
    Jegede, Opeyemi
    Bilen, Mehmet Asim
    Stein, Mark N.
    Sosman, Jeffrey A.
    Alter, Robert S.
    Plimack, Elizabeth R.
    Hurwitz, Michael E.
    Wu, Catherine J.
    Einstein, David Johnson
    Hammers, Hans J.
    Signoretti, Sabina
    West, Destiny
    Denize, Thomas
    Atkins, Michael B.
    Braun, David A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [36] Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.
    McDermott, David F.
    Rini, Brian I.
    Motzer, Robert J.
    Tannir, Nizar M.
    Escudier, Bernard
    Kollmannsberger, Christian K.
    Hammers, Hans J.
    Porta, Camillo
    George, Saby
    Donskov, Frede
    Gurney, Howard
    Grimm, Marc-Oliver
    Harrison, Michael Roger
    Hutson, Thomas E.
    Yang, Shuo
    Johansen, Jennifer
    Rao, Sumati
    Mekan, Sabeen Fatima
    Rael, Michael
    Powles, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [37] EXPLORING HIDDEN SURVIVAL HETEROGENEITY AMONG FIRST-LINE (1L) INTERMEDIATE/POOR (I/P)-RISK ADVANCED RENAL CELL CARCINOMA (ARCC) PATIENTS TREATED WITH NIVOLUMAB PLUS IPILIMUMAB (NIVO plus IPI) VIA PARAMETRIC MIXTURE MODELS (PMM)
    Hunger, M.
    George, S.
    Dyer, M.
    Ejzykowicz, F.
    May, J. R.
    Kurt, M.
    VALUE IN HEALTH, 2023, 26 (06) : S287 - S287
  • [38] Five-year survival outcomes with nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for metastatic non-small cell lung cancer (NSCLC): Results from CheckMate 227.
    Brahmer, Julie R.
    Lee, Jong-Seok
    Ciuleanu, Tudor-Eliade
    Caro, Reyes Bernabe
    Nishio, Makoto
    Urban, Lazio
    Audigier-Valette, Clarisse
    Lupinacci, Lorena
    Sangha, Randeep S.
    Paz-Ares, Luis G.
    Reck, Martin
    Borghaei, Hossein
    O'Byrne, Kenneth John
    Gupta, Ravi
    Bushong, Judith
    Li, Li
    Blum, Steven I.
    Eccles, Laura
    Ramalingam, Suresh S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [39] Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N plus C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC).
    Shah, Amishi Yogesh
    Motzer, Robert J.
    Apolo, Andrea B.
    Powles, Thomas
    Escudier, Bernard
    Zhang, Joshua
    Scheffold, Christian
    Karumanchi, Sravan
    Linh Thuy Nguyen
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.
    Paz-Ares, Luis G.
    Ciuleanu, Tudor-Eliade
    Lee, Jong-Seok
    Urban, Laszlo
    Caro, Reyes Bernabe
    Park, Keunchil
    Sakai, Hiroshi
    Ohe, Yuichiro
    Nishio, Makoto
    Pluzanski, Adam
    Ramalingam, Suresh S.
    Brahmer, Julie R.
    Borghaei, Hossein
    O'Byrne, Kenneth John
    Hellmann, Matthew D.
    Memaj, Arteid
    Bushong, Judith
    Tran, Phuong
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345